Discussing the Role of MRD in CLL With Talal Hilal, MD
The HemOnc Pulse
Navigating the MRD Controversy in CLL
Exploring the challenges and potential benefits of minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL), including discussions on MRD-guided trials, time-limited therapy, targeted agent doublets, and the debate between triplet and doublet therapies.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
